BI 34021

Drug Profile

BI 34021

Alternative Names: BI 34021 FU2; BI34021

Latest Information Update: 16 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 01 Oct 2014 Discontinued - Phase-I for Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)
  • 23 Jun 2008 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02259842)
  • 28 Mar 2008 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, tablet and PO, solution)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top